mRNA vaccines lead next-generation efforts to combat H5N1
The H5N1 virus, known for its 50% human case fatality rate, has persisted globally for over two decades, causing thousands of infections.
The recent outbreaks, including those affecting US dairy cows, have accelerated the development of next-generation vaccines, with mRNA vaccines stepping into the spotlight, aiming to replicate the success achieved during the COVID-19 pandemic, says pharma analytics company GlobalData.
According to GlobalData, while the majority of the 22 vaccine candidates currently in development rely on traditional approaches, mRNA vaccines make up less than 10% of the pipeline. However, the rapid development and potential efficacy seen during the COVID-19 pandemic signal a significant shift in the H5N1 vaccine landscape.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze